drugset / Trial / NCT00480246
A Positron Emission Tomography (PET) Study to Assess the Degree of Dopamine-2 (D2) Receptor Occupancy in the Human Brain After Single Doses of BL-1020 or Perphenazine in Healthy Male Subjects Using [11C]Raclopride as PET Tracer
Non-randomizedParallel-groupOpen-label
Summary
This is a single dose, open-label, 2-panel (Parts A and B) PET study investigating the degree of occupancy of dopamine 2 receptors (D2\_RO) in the human brain after single oral doses of BL-1020 or Perphenazine (Trilafon®, hereafter called Perphenazine) in healthy male subjects. In Part A the D2\_RO is investigated for the study compound BL-1020 and in Part B the D2\_RO of BL-1020 is compared to the D2\_RO of Perphenazine, a reference compound.
Timeline
- Start
- 2007-05
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PERPHENAZINE 4-AMINOBUTYRATE | Small molecule | — | Oral |
| Subject | Perphenazine | Small molecule | — | Oral |
Indications
No indication recorded.